ClinicalTrials.gg
CompletedNCT06842992NH102-21Updated Sep 22, 2026

A Phase II Study to Evaluate NH102 for Depression

A Phase 2 interventional study of NH102 and NH102 in Major Depressive Disorder (MDD), sponsored by Jiangsu Nhwa Pharmaceutical Co., Ltd.. Completed at 24 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-22.

Sponsored by Jiangsu Nhwa Pharmaceutical Co., Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
243
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 206 studies in Depressive Disorder, Major with a site in China — 74 open to participants now, 77 under way, 5 of them phase 3. Depressive Disorder, Major · China.

Enrollment
47th of 173
243 · median 120
Started
2024
with 15 others
Phase 2
19 of 206
3 open now
Registered
157th of 206
by date

Among the 206 studies in Depressive Disorder, Major with a site in China, this one is the 47th largest by enrollment of the 173 interventional ones that give a count, is one of 16 that started in 2024, is one of 19 in phase 2, and was the 157th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

74 of the 206 studies in Depressive Disorder, Major with a site in China are open now. Recruiting first, the newest first:

69 more — sign in →

All 74 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 206 studies in Depressive Disorder, Major with a site in China, or all of them as a file.
02

Study summary

This study is a multicenter, randomized, double-blind, double-dummy, parallel-group, dose-finding Phase II clinical trial with placebo and active comparator duloxetine . It is designed to preliminarily assess the efficacy and safety of NH102 in patients with major depressive disorder and to provide the basis for the design of Phase III clinical trials.

Read the detailed description

This trial consists of three periods: a screening period (up to 2 weeks), a double-blind treatment period (6 weeks), and a tapering-off period/safety follow-up (1 week). The screening period may last up to 14 days and a minimum of 1 day.

Baseline assessments will be conducted prior to randomization to confirm the eligibility of participants. A total of 240 patients with depression will be randomly assigned in a 1:1:1:1:1 ratio to three experimental drug groups (10 mg, 20 mg, and 30 mg), one active control group (duloxetine hydrochloride capsules 60 mg ), or one placebo group. The double-blind treatment period will last for 6 weeks, during which participants will take the assigned medications according to the specified dosing regimen and will be followed up at the end of weeks 1, 2, 4, and 6. After the treatment period, participants will enter a 1-week tapering-off period and will undergo safety follow-up at the end of week 7.

03

Conditions studied

  • Major Depressive Disorder (MDD)
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female outpatients aged 18-65 years (inclusive).
  • Diagnosis of Major Depressive Disorder (MDD) according to criteria ( without psychotic features).
  • Hamilton Depression Rating Scale (HAM-D17) total score ≥ 22 at screening and baseline visits, with item 1 (depressed mood) score ≥ 2.
  • Clinical Global Impression-Severity (CGI-S) score ≥ 4 at screening and baseline.
  • Negative pregnancy test for women of .
  • Willingness to use effective during the trial and for 3 months after the last dose.
  • Voluntary participation and signed .

Exclusion criteria

Exclusion Criteria:

  • Duration of the current depressive episode in first-episode patients \< 3 months.
  • Treatment-resistant depression (failure of ≥ 2 adequate antidepressant treatments).
  • Other psychiatric disorders (e.g., schizophrenia, bipolar disorder, anxiety disorders).
  • History of severe neurological diseases, epilepsy, or significant head trauma.
  • Unstable or severe cardiovascular, gastrointestinal, or endocrine diseases.
  • History of within the past 2 years.
  • History of increased intraocular pressure or untreated narrow-angle glaucoma.
  • Abnormal thyroid function not adequately controlled.
  • History of severe drug allergies or to duloxetine or .
  • Suicide attempt within the past year or significant suicide risk.
  • Substance abuse within the past year or positive at screening drug test.
  • Alcohol abuse (≥ 14 units/week) within the past year.
  • Previous treatment with duloxetine without adequate response.
  • Normative use of antidepressants within 2 weeks prior to screening.
  • Use of CYP2D6 or CYP1A2 potent inhibitors/inducers within 2 weeks prior to screening.
  • Participation in another clinical trial within the past 3 months.
  • Any condition deemed unsuitable by the investigator.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
243 participants (actual)

Study arms

  • Experimental
    NH102 10mg

    Drug: NH102

  • Experimental
    NH102 20mg

    Drug: NH102

  • Experimental
    NH102 30mg

    Drug: NH102

  • Active comparator
    Duloxetine Hydrochloride Enteric Capsules

    Drug: Duloxetine Hydrochloride Enteric-coated Capsule

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • DrugNH102

    5 mg twice daily over 6 weeks, followed by a 1-week tapering period.

  • DrugNH102

    10 mg twice daily over 6 weeks, followed by a 1-week tapering period.

  • DrugNH102

    15 mg twice daily over 6 weeks, followed by a 1-week tapering period.

  • DrugDuloxetine Hydrochloride Enteric-coated Capsule

    30 mg twice daily for 6 weeks, followed by a 1-week tapering period.

  • DrugPlacebo

    Matched dosing regimen.Twice daily for 6 weeks, followed by a 1-week tapering period.

06

What researchers measure

Primary outcomes

  1. 17 items Hamilton Depression Scales (HAM-D17)

    Changes from baseline in the 17 items Hamilton Depression Scales (HAM-D17) total score at the end of treatment. HAM-D17 is a standardized, clinician-administered rating scale that assesses 17 items characteristically associated with major depression (symptoms such as depressed mood, guilty feelings, suicide, sleep disturbances, anxiety levels, and weight loss). Nine items are scored on a 3 point scale (0=none/absent to 2=most severe) and 8 items are scored on a 5 point scale (0=none/absent to 4=most severe) for a maximum total score of 50. Higher scores indicate a worse outcome.

    Time frame: 6 Weeks

Secondary outcomes

  1. 17 items Hamilton Depression Scales (HAM-D17)

    Changes from baseline in the 17 items Hamilton Depression Scales (HAM-D17) total score at Week 2 and 4. HAM-D17 is a standardized, clinician-administered rating scale that assesses 17 items characteristically associated with major depression (symptoms such as depressed mood, guilty feelings, suicide, sleep disturbances, anxiety levels, and weight loss). Nine items are scored on a 3 point scale (0=none/absent to 2=most severe) and 8 items are scored on a 5 point scale (0=none/absent to 4=most severe) for a maximum total score of 50. Higher scores indicate a worse outcome.

    Time frame: Week 2 and 4

  2. Montgomery- Åsberg Depression Rating Scale(MADRS)

    Changes from baseline in the 10-items Montgomery- Åsberg Depression Scales (MADRS) total score at Week 2, Week 4 and the end of treatment. MADRS is a standardized, clinician-administered rating scale that assesses 10 items characteristically associated with major depression. Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms).

    Time frame: 6 Weeks

  3. Clinical Global Impression-Improvement (CGI-I)

    Changes from baseline in the CGI-I score at the end of treatment. The Clinical Global Impression-Improvement (CGI-I) scale is a clinician-rated instrument designed to assess the overall improvement or worsening of a patient's condition relative to a baseline state. The following one query is rated on a seven-point scale: "Compared to the patient's condition at admission to the project, this patient's condition is: 1=very much improved since the initiation of treatment; 2=much improved; 3=minimally improved; 4=no change from baseline (the initiation of treatment); 5=minimally worse; 6= much worse; 7=very much worse since the initiation of treatment."

    Time frame: 6 Weeks

  4. Clinical Global Impression-Severity (CGI-S)

    Changes from baseline in the Clinical Global Impression-Severity (CGI-S) score at the end of treatment. The CGI-S asks the clinician one question: "Considering your total clinical experience with this particular population, how mentally ill is the patient at this time?" which is rated on the following seven-point scale: 1=normal, not at all ill; 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill patients.

    Time frame: 6 Weeks

  5. Hamilton Anxiety Rating Scale (HAM-A)

    Changes from baseline in the HAM-A total score at the end of treatment. The Hamilton Anxiety Rating Scale (HAM-A) is a clinician-administered assessment tool to measure the severity of anxiety symptoms. It consists of 14 items, each evaluating a specific symptom of anxiety, such as anxious mood, tension, fears, and somatic complaints. Each item is scored on a scale from 0 (None) to 4 ( Very severe. grossly disabling ), with the total score ranging from a minimum of 0 to a maximum of 56. Higher scores indicate greater severity of anxiety symptoms, reflecting a worse clinical outcome.

    Time frame: 6 Weeks

  6. Dimensional Anhedonia Rating Scale (DARS)

    Change from baseline in Dimensional Anhedonia Rating Scale (DARS) total score at the end of treatment. The DARS is a self-report scale that measures anhedonia across the following 4 domains: hobbies/past-times, food/drinks, social activities, and sensory experiences. Within each domain, participants are required to provide at least two of their own examples of what they find rewarding. Subsequently, participants answer a set of standardized questions about desire, motivation, effort and consummatory pleasure for the examples provided. Responses were based on a 5-point Likert scale (Not at all=0; Slightly=1; Moderately=2; Mostly=3; Very Much=4), with the total score ranging from a minimum of 0 to a maximum of 68. A higher score reflects a better outcome.

    Time frame: 6 Weeks

07

Study locations

24 sites
  • Anhui Mental Health Center
    Hefei, Anhui 230000, China
  • Beijing Huilongguan Hospital
    Beijing, Beijing Municipality 100096, China
  • Chongqing Mental Health Center
    Chongqing, Chongqing Municipality 400036, China
  • Xiamen Xianyue Hospital
    Xiamen, Fujian 361012, China
  • The Affiliated Brain Hospital of Guangzhou Medical University
    Guangzhou, Guangdong 510370, China
  • Shenzhen Kangning Hospital
    Shenzhen, Guangdong 518118, China
  • Hebei Mental Health Hospital
    Baoding, Hebei 071000, China
  • The Second Affiliated Hospital of Henan Medical University
    Xinxiang, Henan 453000, China
  • Zhumadian Second People's Hospital
    Zhumadian, Henan 463000, China
  • Hunan Second people's Hospital
    Changsha, Hunan 410007, China
  • Suzhou Guangji Hospital
    Suzhou, Jiangsu 215000, China
  • Wuxi Mental Health Center
    Wuxi, Jiangsu 214000, China
  • Nanchang Mental Health Center
    Nanchang, Jiangxi 330038, China
  • Jilin Provincial Neuropsychiatric Hospital
    Siping, Jilin 136000, China
  • Shongdong Mental Health Center
    Jinan, Shandong 250014, China
  • Shanghai Mental Health Center
    Shanghai, Shanghai Municipality 200030, China
  • Frist Hospital of Shanxi Medical University
    Taiyuan, Shanxi 030000, China
  • Xi'an Mental Health Center
    Xi’an, Shanxi 710000, China
  • The Fourth People's Hospital of Chengdu
    Chengdu, Sichuan 610000, China
  • Sichuan Provincial People's Hospital
    Chengdu, Sichuan 610072, China
  • Tianjin Anding Hospital
    Tianjin, Tianjin Municipality 300000, China
  • Hangzhou Seventh People's Hospital
    Hangzhou, Zhejiang 310003, China
  • Huzhou Third Municipal Hospital
    Huzhou, Zhejiang 313000, China
  • The Affiliated Kangning Hospital of Ningbo University
    Ningbo, Zhejiang 315000, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2024 to primary completion in Jul 2025, 7 months.

Of 96 industry-sponsored phase 2 interventional studies under Depressive Disorder, Major, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 23. This study's 7 months is below that.

Counting every sponsor, half of 195 studies reached it within 22 months; a quarter within 14 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 16, 2025
First posted
Feb 24, 2025
StartActual
Dec 4, 2024
Primary completionActual
Jul 30, 2025
CompletionActual
Sep 12, 2025
Last update
Sep 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06842992
Lead sponsor
Jiangsu Nhwa Pharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Feb 24, 2025
Start date
Dec 4, 2024
Primary completion
Jul 30, 2025
Completion
Sep 12, 2025
Last update
Sep 22, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: NH102

Start the discussion